Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226882 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults
A Phase 3 study of Lyme Borreliosis, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 5
- Study locations
NCT07226882 is a Phase 3 study of Lyme Borreliosis that is actively recruiting participants, run by Pfizer. The registered enrollment target is 200 participants. The trial reports 5 study locations across 2 states.
The verdict
NCT07226882, a Phase 3 study of Lyme Borreliosis, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to learn about the safety and effects of the Lyme disease vaccine (called VLA15) when given at different time points. This study is seeking participants who: * are generally healthy and between 18 and 44 years of age, * have never had a vaccine for Lyme disease before, * are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners, and * are not pregnant or breastfeeding and do not plan to become pregnant while receiving the study vaccine. All participants in this study will receive a total of 5 doses through a shot in the upper arm. Four doses will be the study vaccine (VLA15), and 1 dose will be saltwater. The study will compare the experiences of people receiving the study vaccine at different time points. This will help see if the study vaccine is safe and will help understand its effect on the body. Participants will take part in this study for about 2 years. During this time, the participants will have 11 planned visits - 8 will be at the study clinic and 3 will be done over the phone. The clinic visits may include having a health check, giving a small amount of blood (about 20 mL or 4 teaspoons), and getting the study vaccine or saltwater as a shot.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VLA15
Study Locations (5)
Pennsylvania
- Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18) - Pittsburgh
- Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair - Pittsburgh
- Preferred Primary Care Physicians - Uniontown
Virginia
- Clinical Research Partners, LLC - Richmond
- Amherst Family Practice, P.C. - Winchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-11-19 |
| Est. Completion | 2028-02-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226882
The ClinicalTrials.gov registry entry for NCT07226882 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lyme Borreliosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07226882 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Virginia.
Frequently Asked Questions
What is clinical trial NCT07226882 about?
NCT07226882 is a clinical study titled "A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults". The purpose of this study is to learn about the safety and effects of the Lyme disease vaccine (called VLA15) when given at different time points. This study is seeking participants who: * are generally healthy and between 18 and 44 years of age, * have never had a vaccine for Lyme disease before,...
What is the current status of trial NCT07226882?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2025-11-19. Estimated completion is 2028-02-14.
What conditions does trial NCT07226882 study?
This clinical trial studies the following conditions: Lyme Borreliosis.
What interventions are being tested in trial NCT07226882?
The interventions under investigation include: Placebo (BIOLOGICAL), VLA15 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07226882?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226882 being conducted?
This trial has 5 study locations across Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lyme Borreliosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.